Clinical trials: Sunitinib
- Drug or intervention Sunitinib
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Bioequivalence
The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions
The study is designed in accordance with the Eurasian Economic Union (EAEU) regulatory guidelines, with the aim of characterizing the bioavailability of two pharmaceutical products of sunitinib in healthy adult volunteers.
- Trial name
- NCT05218616
- Testing
- Aviga, capsules 50 mg / Sutent®, capsules 50 mg, Sutent®, capsules 50 mg / Aviga, capsules 50 mg
- Where
- Belarus
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- JLLC NatiVita
Gastrointestinal Stromal Tumors, Renal Cell Carcinoma
A Bioequivalence Study of Sunitinib Malate Capsules.
A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of…
- Conditions
- Gastrointestinal Stromal Tumors, Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT05800106
- Testing
- Sunitinib malate capsules generic product, Sunitinib malate capsules reference product
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.